poisar

Stocks · News reference

8-K filing — EXICURE, INC. (XCUR)

SEC EDGARSEC EDGAR

Filed: 2026-11-10 AccNo: 0001193125-26-455339 Size: 854 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion

    Exicure announced the sale of its GPC-100 (burixafor) program assets to South Korean company GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion). The transaction includes clinical data, intellectual property, and related materials from the Phase 2 clinical trial completed in January 2026. GPCRT will assume future milestone and royalty obligations, while Exicure retains liabilities incurred before September 1, 2026. The sale is part of Exicure's strategic alternatives evaluation to maximize stockholder value.